The epidemiology segment also provides the Musculoskeletal Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report includes the prevalent scenario of Musculoskeletal Pain in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.Ĭountry-wise Musculoskeletal Pain Epidemiology The disease epidemiology covered in the report provides historical and forecasted Musculoskeletal Pain epidemiology segmented as the Diagnosed Prevalent cases of Musculoskeletal Pain, Age-specific cases of Musculoskeletal Pain, and Gender-specific cases of Musculoskeletal Pain. It is anticipated that with the launch of key assets like Ampion (Ampio Pharmaceuticals), CAM2038 (Braeburn Pharmaceuticals), CNTX-4975 (Centrexion Therapeutics), and fasinumab, the market size would witness expedited growth during the forecasted period.

This part of the report also provides the diagnosed patient pool, trends, and assumptions.Ĭompanies such as Mesoblast, Mitsubishi Tanabe Pharma, Regeneron Pharmaceuticals, Ampio Pharmaceuticals, Charleston Laboratories, Sorrento Therapeutics, Centrexion Therapeutics, MDM S.p.A., Braeburn Pharmaceuticals, and Taiwan Liposome Company are actively involved in developing therapies for the treatment of MSP. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The Musculoskeletal Pain epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries.

This 'Musculoskeletal Pain - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology of Musculoskeletal Pain in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. DUBLIN, November 11, 2021-( BUSINESS WIRE)-The 'Musculoskeletal Pain - Epidemiology Forecast to 2030' drug pipelines has been added to 's offering.

Kirby s kjar mdm